Incyte Corporation
COMBINATION THERAPY WITH AN ANTI-CD19 ANTIBODY AND PARSACLISIB

Last updated:

Abstract:

The present disclosure describes a combination of an anti-CD19 antibody and parsaclisib for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.

Status:
Application
Type:

Utility

Filling date:

30 Nov 2021

Issue date:

4 Aug 2022